VivoSeq
Psychiatry

Autism Spectrum Disorder

129

Pipeline Programs↗

51

Active Trials↗

65

Companies Involved↗

Autism Spectrum Disorder is a highly competitive landscape with 129 programs across 65 companies. The most active players are Coronado Biosciences, Inc., Azurity Pharmaceuticals, Lykos Therapeutics. 21 therapies are approved with 17 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

75/100

Pipeline Velocity

43/100

Mech. Concentration

6/100

Completion Rate

75/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Coronado Biosciences, Inc.

1 program

Phase 1A

Azurity Pharmaceuticals

1 program

Phase 1L

Lykos Therapeutics

1 program

Phase 1Amgen logo

Amgen

1 program

Phase 1M

Mononuclear Therapeutics Ltd.

1 program

Phase 1A

Aardvark Therapeutics, Inc.

2 programs

Phase 2

Pipeline

Programs by Phase

Preclinical24

Psilocybin

COMPASS Pathways

Sapropterin Dihydrochloride

BioMarin Pharmaceutical

Dexmedetomidine

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Naltrexone

Teva

Fluconazole

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 116

Riluzole

Azurity Pharmaceuticals

Citalopram

AbbVie

Midomafetamine

Lykos Therapeutics

Vasopressin

Aultman Health Foundation

Propranolol

Wyeth-Lederle Vaccines

Phase 251

Escitalopram

AbbVie

Pyridoxine

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Magnesium

Spherium Biomed

Pitolisant

Harmony Biosciences Management, Inc.

Sulforaphane

Eastern Cooperative Oncology Group

Phase 317

Cariprazine

AbbVie

Melatonin

Neurim Pharmaceuticals Ltd.

Lithium Carbonate

Solvay Pharmaceuticals

Bumetanide

Validus Pharmaceuticals

Metformin

EMD Serono

Approved21

Baclofen

Novartis

Levodopa

Merz Pharmaceuticals GmbH

Buspirone

Bristol-Myers Squibb

Aripiprazole

Otsuka

Acetylcysteine

Arbor Pharmaceuticals, Inc.

Analysis

Modality Breakdown

99%

Small molecule

143 of 144 classified programs — the dominant modality here.

1%ALL OTHERSCell therapy1<1%

Small molecule leads; the ring shows all 144 classified programs, each share of the total. Modality classified for 99% of 161 pipeline programs.

Analysis

Trial Status

184

clinical trials

Completed91 · 49%
Recruiting26 · 14%
Terminated20 · 11%
Not yet recruiting14 · 8%
Unknown status11 · 6%
Withdrawn9 · 5%
Other13 · 7%

Clinical Trials

Trial Activity

184 trials

Oxytocin Effects on Bone in Children With Autism Spectrum Disorder
Recruiting·—·Phase 2·NCT05754073·96 enrolled
Suramin for the Treatment of Autism Trial: KZ101 in a Male Pediatric Population With Autism Spectrum Disorder (ASD)
Recruiting·—·Phase 2·NCT06866275·45 enrolled
Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium
Recruiting·SSouthwest Autism Research & Resource Center·Phase 2·NCT04060017·80 enrolled
WMT for Autism Spectrum Disorder (ASD)
Recruiting·TThe Second Hospital of Nanjing Medical University·Phase 1·NCT06030752·80 enrolled
Safety, Tolerability and Pharmacokinetics of Lumateperone in Pediatric Patients With Autism Spectrum Disorder
Recruiting·IIntra-Cellular Therapies, Inc.·Phase 1·NCT06557902·26 enrolled
SCI-210 in the Treatment of Children and Young Adults With AutismEvaluate the Safety, Tolerability and Efficacy of SCI-210 in Children With Autism Spectrum Disorder (ASD)
Recruiting·NNeurothera Labs Inc.·N/A·NCT05182697·60 enrolled
Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder
Recruiting·NNew York State Psychiatric Institute·Phase 2·NCT05999240·30 enrolled
Phase II Clinical Trial to Evaluate the Efficacy and Safety of NV01-A02 in Children With Autism Spectrum Disorder
Recruiting·NNeuroventi Inc.·Phase 2·NCT06951854·105 enrolled
Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)
Recruiting·MMontefiore Medical Center·Phase 2·NCT03202303·100 enrolled
A Phase 2A Trial of MM402 for Autism Spectrum Disorder
Recruiting·DDefinium Therapeutics US, Inc.·Phase 2·NCT07303907·20 enrolled
AWARE: Management of ADHD in Autism Spectrum Disorder
Recruiting·—·Phase 4·NCT05916339·500 enrolled
Combined Photo-Biomodulation At Acupuncture Points, Autologous PRP, and Umbilical Cord-Derived Exosome Therapy in Autism Spectrum Disorder
Recruiting·IIffat Anwar Medical Complex·N/A·NCT06600529·100 enrolled
Omic Profile in Autism Spectrum Disorder: From Cellular Level Towards Future Treatments
Recruiting·FFondazione I.R.C.C.S. Istituto Neurologico Carlo Besta·N/A·NCT07427940·100 enrolled
Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances
Recruiting·VVanda Pharmaceuticals·Phase 3·NCT05361707·100 enrolled
TB006 for Autism Spectrum Disorder
Recruiting·RRossignol Medical Center·Phase 2·NCT06500637·45 enrolled
Page 1 of 13

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)